VACCINE OVERLOAD: TWO NEW PNEUMOCOCCAL VACCINES ARE NOW AVAILABLE
February 3, 2022 - Most people have gotten their fill of vaccine news in the past year, but it didn't stop Pfizer and Merck from introducing two new pneumococcal vaccines. The Pfizer product is called Prevnar 20, and the Merck product is Vaxneuvance. The addition of these two vaccines now means that there are four pneumococcal vaccines available for adults. A breakdown of each vaccine is provided below, along with a review of their efficacy.
- Pneumovax (PPSV23) - PPSV23 is a vaccine from Merck that covers 23 serotypes of Streptococcus pneumoniae. PPSV23 has been available since 1983, and the CDC currently recommends that all people 65 years and older receive at least one dose.
- Prevnar 13 (PCV13) - PCV13 is a conjugate vaccine from Pfizer that covers 13 serotypes of Streptococcus pneumoniae. PCV13 has been available since 2010 and is part of the recommended childhood immunization schedule. In adults, the CDC used to recommend that all people 65 years and older routinely receive PCV13 and PPSV23. In 2019, they dropped PCV13 from the recommendation because PCV13 use in children has led to a sharp decline in pneumococcal disease among adults.
- Prevnar 20 (PCV20) - PCV20 is a conjugate vaccine from Pfizer that covers 20 serotypes of Streptococcus pneumoniae. The vaccine was FDA-approved in 2021.
- Vaxneuvance (PCV15) - PCV15 is a conjugate vaccine from Merck that covers 15 serotypes of Streptococcus pneumoniae. The vaccine was FDA-approved in 2021.
So, just how effective are pneumococcal vaccines? There is no real-world data on the two new vaccines (PCV20 and PCV15), as their approvals were based on antibody titers, a surrogate endpoint. The largest randomized controlled trial to look at the efficacy of pneumococcal vaccines was performed in the Netherlands, where 84,496 adults aged 65 years or older (mean age 73 years) were randomized to PCV13 or placebo. After an average follow-up of 3.97 years, 0.32% of patients who received PCV13 had confirmed pneumococcal community-acquired pneumonia (CAP) compared to 0.41% in the placebo group (p=0.05). The PCV13 group had a lower incidence of CAP caused by pneumococcal strains covered in the vaccine (0.15% vs 0.25%, p=0.003), but there was no significant difference in overall cases of CAP (1.8% vs 1.9%, p=0.32) or all-cause mortality (7.1% vs 7.1%). [PubMed abstract]
As for PPSV23, no large randomized trials involving the general public have been published. Small studies that have examined its effects in high-risk patients have been mostly disappointing - PMID 28122642, PMID 9482293, PMID 20211953, PMID 10902624.
Vaccine approvals translate to big bucks for pharmaceutical companies, especially if they can become part of the CDC's routine vaccine recommendations. This means millions of people will receive the vaccine each year without question when their provider recommends it; not to mention, many providers are "graded" by Medicare and other healthcare entities on the vaccination status of their patients. The CDC's Advisory Committee on Immunization Practices has already recommended that PCV20 replace PPSV23, and Pfizer is running ads suggesting people get PCV20 even if they've already had another pneumococcal vaccine.
There is no question that vaccines save lives, but in some cases, the overall benefit is debatable, and it seems fair to question recommendations that call for the routine vaccination of large populations. Unless PCV20 and PCV15 prove to be far superior to PCV13, we'll have two more vaccines that lower the risk of pneumococcal CAP by around 0.10% while having no effect on mortality.